Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
300 participants
INTERVENTIONAL
2022-09-14
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
NCT04023253
Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
NCT03558919
Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.
NCT04500860
Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females
NCT07312955
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome
NCT05040984
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A : patients will receive mirabegron
patients will receive mirabegron
Mirabegron
pills taken once day
Group B: patients will receive tadalafil 5mg
patients will receive tadalafil 5mg
Tadalafil 5mg
pills taken once day
Group C: patients will receive solfenacin
patients will receive solfenacin
Solfenacin
pills taken once day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Solfenacin
pills taken once day
Mirabegron
pills taken once day
Tadalafil 5mg
pills taken once day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Severe neurogenic dysfunction.
* Drug administration which interfere with bladder function .
* Abnormal bleeding profile.
* A verified urinary tract infection as determined by urinalysis and/or urine culture during screening
18 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Elsayed Abdelhalim Elsayed
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elsayed Abdelhalim Elsayed
assistant lecturer, urology department, Kafrelsheikh university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kafrelsheikh University hospital
Kafr ash Shaykh, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OAB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.